Skip to main content
. 2023 Jan 28;9(2):e13211. doi: 10.1016/j.heliyon.2023.e13211

Fig. 4.

Fig. 4

TAMs are associated with OS of 100 CRC patients. A, Kaplan-Meier survival analyses for the association of the expressions of pan-monocyte/macrophage marker (CD68), M1 macrophage markers (NOS2, CXCL10 and CD11c) or M2 macrophage markers (CD163, CD206 and CD115) with patient OS. B, Kaplan-Meier survival analyses for the association of concurrent double expressions of M1 markers (NOS2 and CXCL10, NOS2 and CD11c, CXCL10 and CD11c) or M2 markers (CD163 and CD206, CD163 and CD115, CD206 and CD115) with patient OS. C, Kaplan-Meier survival analyses for the concurrent triple expressions of M1 macrophage markers (NOS2, CD11c and CXCL10) or M2 macrophage markers (CD163, CD206 and CD115) with patient OS. **P < 0.01, ***P < 0.001.